Lucius LuciAcor Acoramidis 356mg

Product Information

• Product name: LuciAcor Acoramidis 356mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Acoramidis
• Current strength: 356mg
• SKU: LU-ITEM-16
• Site category: cardiomyopathy, other cancer

Product Summary

LuciAcor Acoramidis 356mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Acoramidis is the active ingredient used for this product page. Public prescribing information for Acoramidis was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

Acoramidis is a selective stabilizer of transthyretin (TTR). Acoramidis binds TTR at thyroxine binding sites and slows dissociation of the TTR tetramer into its constituent monomers, the rate-limiting step in amyloidogenesis.

Reference Indications

Acoramidis is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. Acoramidis is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

Reference Dosage and Administration

Recommended dosage of Acoramidis is 712 mg orally twice daily. with or without food).

With this 356mg product, that corresponds to 2 x 356mg tablets when that reference dose is clinically appropriate.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

Safety risks must be reviewed from the current package insert and by a healthcare professional. Prescription medicines may involve serious adverse reactions, contraindications, monitoring requirements, and drug interactions.

Common Adverse Reactions and Monitoring

The safety data reflect the exposure of 421 participants with ATTR-CM to Acoramidis 712 mg (administered as two 356 mg tablets) administered orally twice daily in a randomized, double-blind, placebo-controlled trial of 30 months fixed treatment duration. The median duration of exposure to Acoramidis in the safety population was 29 months. A similar proportion of Acoramidis-treated and placebo-treated participants discontinued study drug because of an adverse event (9.3% and 8.5%, respectively).

Drug Interactions and Special Populations

UDP-glucuronosyltransferases (UGT) Inducers and Strong CYP3A Inducers Acoramidis is metabolized by UGT enzyme-mediated glucuronidation. Concomitant use of UGT inducers can potentially decrease acoramidis exposure. While acoramidis is not metabolized by CYP3A, strong CYP3A inducers can also induce UGT enzymes. Avoid concomitant use of Acoramidis with UGT inducers and strong CYP3A inducers. Sensitive Cytochrome P450 2C9 (CYP2C9) substrates Acoramidis inhibits CYP2C9 and may result in an increase in CYP2C9 substrate concentrations when these drugs are co administered. Consider more frequent monitoring of patients for evidence of increased exposure (for example, signs of exposure related toxicity) when Acoramidis is co administered with sensitive CYP2C9 substrates.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: Attruby public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.